APTOF · As filed with the SEC
Aptose Biosciences income statement, by fiscal year
The statement as Aptose Biosciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Loss and Comprehensive Loss · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 |
|---|---|---|
| Revenue | 0 | 0 |
| Operating expenses: | ||
| Research and development | 11,341,000 | 15,103,000 |
| General and administrative | 13,382,000 | 11,154,000 |
| Total operating expenses | 24,723,000 | 26,257,000 |
| Other income (expenses): | ||
| Interest income | 105,000 | 357,000 |
| Interest expense, related party | (843,000) | (207,000) |
| Change in fair value of warrants | 0 | 686,000 |
| Foreign exchange loss | (7,000) | (9,000) |
| Total other (expenses) income | (745,000) | 827,000 |
| Net loss and comprehensive loss | (25,468,000) | (25,430,000) |
| Net loss per common share, basic | (10.41) | (36.38) |
| Net loss per common share, diluted | (10.41) | (36.38) |
| Weighted-average number of common shares outstanding, basic | 2,447,353 | 698,980 |
| Weighted-average number of common shares outstanding, diluted | 2,447,353 | 698,980 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.